| scholarly article | Q13442814 |
| P50 | author | Richard Greil | Q15438434 |
| Hubert Hackl | Q41547884 | ||
| P2093 | author name string | Bernd Lamprecht | |
| David Lang | |||
| Lukas Weiss | |||
| Georg Hutarew | |||
| Gabriel Rinnerthaler | |||
| Florian Huemer | |||
| Simon Peter Gampenrieder | |||
| Theresa Westphal | |||
| P2860 | cites work | Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers? | Q95579825 |
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Inflammation and cancer | Q24649640 | ||
| Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis | Q27022482 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| Cancer-related inflammation | Q27860907 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer | Q29620301 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Enhancement of an anti-tumor immune response by transient blockade of central T cell tolerance | Q33569842 | ||
| Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology | Q33890538 | ||
| Neoantigens in cancer immunotherapy. | Q34470074 | ||
| Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer | Q36648454 | ||
| The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. | Q36887861 | ||
| PD-L1 Expression in Lung Cancer | Q37704352 | ||
| The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer | Q38100418 | ||
| European cancer mortality predictions for the year 2016 with focus on leukaemias | Q38915866 | ||
| Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
| Cancer Statistics, 2017. | Q39038674 | ||
| The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma | Q39341329 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. | Q40164456 | ||
| Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. | Q40408396 | ||
| Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients. | Q40535967 | ||
| Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. | Q41369903 | ||
| Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial | Q44958693 | ||
| Tumor Mutational Burden and Response Rate to PD-1 Inhibition. | Q47270933 | ||
| Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab | Q47369863 | ||
| Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer | Q47419988 | ||
| Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer | Q47450132 | ||
| Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors | Q48373246 | ||
| Nivolumab versus docetaxel in previously treated advanced non-small cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases | Q50161502 | ||
| Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. | Q51054343 | ||
| Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. | Q51372253 | ||
| PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. | Q51799211 | ||
| Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. | Q52586557 | ||
| Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. | Q52586565 | ||
| Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer. | Q52718909 | ||
| Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small cell lung cancer. | Q52721675 | ||
| Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. | Q52758014 | ||
| RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer | Q56892940 | ||
| Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | Q57069952 | ||
| Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer | Q57069963 | ||
| Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors | Q58129840 | ||
| The role of neoantigen in immune checkpoint blockade therapy | Q59339934 | ||
| Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study | Q85448625 | ||
| Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC | Q88973544 | ||
| NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018 | Q90101749 | ||
| The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC | Q90595406 | ||
| Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics | Q91250504 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| P577 | publication date | 2019-07-10 | |
| P1433 | published in | Journal of Clinical Medicine | Q27724774 |
| P1476 | title | Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade | |
| P478 | volume | 8 |
Search more.